DAC Patient Recruitment Debuts Updated DACTracks Clinical Trial Metrics Software - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
DAC Patient Recruitment Debuts Updated DACTracks Clinical Trial Metrics Software

Source: Company News Release

As a clinical trial sponsor, being able to measure research programs with pinpoint accuracy is a valuable proposition. That's precisely what DAC Patient Recruitment Services (DAC), an Imperial company and a leader in clinical trial patient recruitment and retention, offers through its proprietary DACTracks™ technology.

"Evaluating real-time program data is essential in analyzing return on investment," said DAC Vice President of Operations Melynda Geurts. "That is why DAC created DACTracks. This active, online reporting system keeps valuable program data at our clients' fingertips."

Sponsors will enjoy 24-hour access to reports on their research sites' screenings, referrals, randomizations (projected and actual), enrollment, attrition, and more. Both site-specific and global data are available. Impact graphs map recruitment trends following the launch of specific initiatives, and charts display the number of aggregate and site-specific referrals color-coded by source. The retention page features the total number of active and non-active subjects in the study and a summary of discontinued subjects, including reasons for discontinuation.

DACTracks also provides comprehensive statistics on study website performance, including unique site visitors, page views, online pre-qualification, and web traffic sources. Regarding the latter, users will be able to discern at the click of a mouse whether web traffic originated from search engines, referring sites or direct traffic to the study website URL.

For more information about DACTracks, and to sign up for a free demonstration, visit www.imperialcrs.com/dac/dactracks or write to recruit@dacprs.com.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
88%
Borrow lightly from EMA's pathway program?
4%
Create entirely its own pathway program?
8%
View Results
Untitled Document
Source: Company News Release,
Click here